Pituitary Apoplexy After a Single Dose of Long-Acting Octreotide


Autoria(s): CHANG, Claudia Veiga; FELICIO, Andre Carvalho; NUNES, Vania dos Santos; CUNHA-NETO, Malebranche Berardo Carneiro da; CASTRO, Ana Valeria Barros de
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Pituitary apoplexy (PA) is a rare and potentially life-threatening syndrome resulting from an acute infarction or hemorrhage of the pituitary gland. Although the pathogenesis is not fully understood, some predisposing factors such as pituitary stimulation tests, diabetes mellitus, anticoagulant or antiplatelet aggregation therapy, head trauma, and high blood pressure may play a role in its pathophysiology. Octreotide is the mainstay of medical treatment for acromegaly. The majority of reported complications of octreotide therapy are gastrointestinal. We report the case of a 51-year-old acromegalic woman who developed pituitary apoplexy within the context of high blood pressure and a single dose of long-acting octreotide. Our data suggest that the combination of hypertension and octreotide therapy enhances the risk of pituitary apoplexy.

Identificador

ENDOCRINOLOGIST, v.20, n.1, p.15-16, 2010

1051-2144

http://producao.usp.br/handle/BDPI/23167

10.1097/TEN.0b013e3181cb47fc

http://dx.doi.org/10.1097/TEN.0b013e3181cb47fc

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

Relação

Endocrinologist

Direitos

restrictedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #acromegaly #pituitary apoplexy #octreotide #hypertension #CLINICAL-FEATURES #ADENOMAS #SOMATOSTATIN #MANAGEMENT #APOPTOSIS #SHRINKAGE #SURGERY #Endocrinology & Metabolism
Tipo

article

original article

publishedVersion